VEA
PLRX icon

Virtus ETF Advisers’s Pliant Therapeutics PLRX Stock Holding History

Virtus ETF Advisers’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,133
Closed -$67.6K – 694
2024
Q4 		$67.6K Sell
5,133
-2,564
-33% -$35K 0.03% 401
2024
Q3 		$86.3K Buy
7,697
+134
+2% +$1.68K 0.04% 399
2024
Q2 		$81.3K Buy
7,563
+2,396
+46% +$30.9K 0.04% 399
2024
Q1 		$77K Sell
5,167
-354
-6% -$5.84K 0.04% 397
2023
Q4 		$100K Buy
5,521
+1,455
+36% +$22.1K 0.06% 361
2023
Q3 		$70.5K Sell
4,066
-403
-9% -$6.99K 0.04% 384
2023
Q2 		$81K Sell
4,469
-810
-15% -$19.2K 0.05% 427
2023
Q1 		$140K Sell
5,279
-2,024
-28% -$57.6K 0.08% 320
2022
Q4 		$141K Buy
+7,303
New +$153K 0.07% 363
2022
Q2 		– Sell
-10,224
Closed -$72K – 465
2022
Q1 		$72K Sell
10,224
-603
-6% -$6.15K 0.03% 348
2021
Q4 		$146K Buy
10,827
+4,361
+67% +$69.3K 0.06% 356
2021
Q3 		$109K Sell
6,466
-333
-5% -$7.07K 0.05% 376
2021
Q2 		$198K Sell
6,799
-4,151
-38% -$129K 0.08% 352
2021
Q1 		$431K Buy
10,950
+191
+2% +$6.2K 0.18% 167
2020
Q4 		$244K Buy
+10,759
New +$270K 0.1% 319

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Virtus ETF Advisers's PLRX Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Pliant Therapeutics (PLRX) in Q1 2025, closing a stake of 5,133 shares — an estimated $67.6K sold.

Virtus ETF Advisers first reported a position in PLRX in Q4 2020 and held it in 15 quarters. The position peaked at $431K in Q1 2021. 140 funds tracked by Wall St. Rank hold PLRX as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Pliant Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 5,133 Pliant Therapeutics shares in Q1 2025, an estimated $67.6K.
  • Virtus ETF Advisers first reported a position in Pliant Therapeutics in Q4 2020 and held it in 15 quarters.
  • Virtus ETF Advisers's Pliant Therapeutics position peaked at $431K in Q1 2021.
  • 140 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.